Strategies for the prevention of hepatocellular carcinoma in the context of chronic viral hepatitis;Strategien zur prävention des hepatozellulären karzinoms bei der hepatitis-virus-infektion

Zeitschrift fur Gastroenterologie

Volumn 46, Issue 1, 2008, Pages 69-80

  Bergk, A ^a   Berg, T ^a   Schott, Eckart ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Hepatitis B; Hepatitis C; Liver; Viral hepatitis

Indexed keywords

ADEFOVIR; AFLATOXIN; ALPHA INTERFERON; ENTECAVIR; HEPATITIS B VACCINE; LAMIVUDINE; PENTOXIFYLLINE; PREDNISOLONE; RAPAMYCIN; TELBIVUDINE; TENOFOVIR;

CANCER PREVENTION; CANCER RISK; CHRONIC HEPATITIS; DISEASE COURSE; HEPATITIS B; HEPATITIS C; HUMAN; HYGIENE; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MORTALITY; REVIEW; VACCINATION;

ADULT; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CHILD; FEMALE; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; META-ANALYSIS AS TOPIC; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; RISK-TAKING;

EID: 39349116029     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-963684     Document Type: Review

References (110)

1. Bosch FX, Ribes J, Diaz M et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127 (5 Suppl 1): S5-S16
2. Kubicka S, Rudolph KL, Hanke M et al. Hepatocellular carcinoma in Germany: a retrospective epidemiological study from a low-endemic area. Liver 2000; 20 (4): 312-318
3. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11 (2): 97-107
4. Yang HI, Lu SN, Liaw YF et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347 (3): 168-174
5. Chan HL, Hui AY, Wong ML et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004; 53 (10): 1494-1498
6. Livingston SE, Simonetti JP, McMahon BJ et al. Hepatitis B virus genotypes in alaska native people with hepatocellular carcinoma: preponderance of genotype f. J Infect Dis 2007; 195 (1): 5-11
7. Tanaka Y, Mukaide M, Orito E et al. Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. J Hepatol 2006; 45 (5): 646-653
8. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama 2006; 295 (1): 65-73
9. Pollicino T, Squadrito G, Cerenzia G et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004; 126 (1): 102-110
10. Fattovich G, Giustina G, Christensen E et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 2000; 46 (3): 420-426
11. Bruno S, Silini E, Crosignani A et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997; 25 (3): 754-758
12. Squadrito G, Pollicino T, Cacciola I et al. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer 2006; 106 (6): 1326-1230
13. Colombo M, Kuo G, Choo QL et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989; 2 (8670): 1006-1008
14. Fattovich G, Stroffolini T, Zagni I et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127 (5 Suppl 1): S35-50
15. Wang LY, Hatch M, Chen CJ et al. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int J Cancer 1996; 67 (5): 620-625
16. Bressac B, Kew M, Wands J et al. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350 (6317): 429-431
17. Hsu IC, Metcalf RA, Sun T et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350 (6317): 427-428
18. Chang MH, Chen CJ, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336 (26): 1855-1859
19. RKI. Epidemiologisches Bulletin Nr. 32. 2003
20. RKI. Epidemiologisches Bulletin Nr. 46. 2005
21. GAVI. Global alliance for vaccines and immunization. www.gavialliance.org
22. Bronowicki JP, Venard V, Botte C et al. Patient-to-patient transmission of hepatitis C virus during colonoscopy. N Engl J Med 1997; 337 (4): 237-240
23. Kaufmann M, Bode JC. Risk of hepatitis C virus infection in medical occupations. Versicherungsmedizin 1997; 49 (4): 132-134
24. Terrault NA. Sexual activity as a risk factor for hepatitis C. Hepatology 2002; 36 (5 Suppl 1): S99-105
25. Wild CP, Hall AJ. Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res 2000; 462 (2-3): 381-393
26. Mommeja-Marin H, Mondou E, Blum MR et al. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003; 37 (6): 1309-1319
27. Lin SM, Sheen IS, Chien RN et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29 (3): 971-975
28. Fattovich G, Giustina G, Realdi G et al. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1997; 26 (5): 1338-1342
29. van Zonneveld M, Honkoop P, Hansen BE et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39 (3): 804-810
30. Lin SM, Yu ML, Lee CM et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46 (1): 45-52
31. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001; 34 (2): 306-313
32. Lampertico P, Del Ninno F, Vigano M et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003; 37 (4): 756-763
33. Camma C, Giunta M, Andreone P et al. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001; 34 (4): 593-602
34. Colonno RJ, Genovesi EV, Medina I et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 2001; 184 (10): 1236-1245
35. Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351 (15): 1521-1431
36. Jaeckel E, Cornberg M, Wedemeyer H et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345 (20): 1452-1457
37. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358 (9286): 958-965
38. Fried MW, Shiffman ML, Ready KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347 (13): 975-982
39. Poynard T, McHutchison J, Manns M et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122 (5): 1303-1313
40. Hayashi N, Kasahara A. Interferon for decreasing the incidence of hepatocellular carcinoma in patients with chronic hepatitis C. Oncology 2002; 62 (Suppl 1): 87-93
41. Ikeda K, Saitoh S, Arase Y et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29 (4): 1124-1130
42. Ikeda K, Arase Y, Saitoh S et al. Anticarcinogenic impact of interferon on patients with chronic hepatitis C: a large-scale long-term study in a single center. Intervirology 2006; 49 (1-2): 82-90
43. Bruno S, Stroffolini T, Colombo M et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45 (3): 579-587
44. Nishiguchi S, Shiomi S, Nakatani S et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001; 357 (9251): 196-197
45. Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther 2001; 15 (5): 689-698
46. Saller R, Meier R, Brignoli R. The use of Silymarin in the treatment of liver diseases. Drugs 2001; 61 (14): 2035-2063
47. Windmeier C, Gressner AM. Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Gen Pharmacol 1997; 29 (2): 181-196
48. Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Cochrane Database Syst Rev 2005: CD002148
49. Orlent H, Hansen BE, Willems M et al. Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. J Hepatol 2006; 45 (4): 539-546
50. Arase Y, Ikeda K, Murashima N et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997; 79 (8): 1494-1500
51. Habu D, Shiomi S, Tamori A et al. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. Jama 2004; 292 (3): 358-361
52. Wang JS, Shen X, He X et al. Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China. J Natl Cancer Inst 1999; 91 (4): 347-354
53. Luo H, Tang L, Tang M et al. Phase IIa chemoprevention trial of green tea polyphenols in high-risk individuals of liver cancer: modulation of urinary excretion of green tea polyphenols and 8-hydroxydeoxyguanosine. Carcinogenesis 2006; 27 (2): 262-268
54. Gelatti U, Covolo L, Franceschini M et al. Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case-control study. J Hepatol 2005; 42 (4): 528-534
55. Tanaka K, Hara M, Sakamoto T et al. Inverse association between coffee drinking and the risk of hepatocellular carcinoma: a case-control study in Japan. Cancer Sci 2006; 8: 8
56. Montella M, Polesel J, La Vecchia C et al. Coffee and tea consumption and risk of hepatocellular carcinoma in Italy. Int J Cancer 2007; 120 (7): 1555-1559
57. Larsson SC, Wolk A. Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology 2007; 132 (5): 1740-1745
58. Greten TF, Blum HE, Manns MP et al. Treatment of hepatocellular carcinoma. Z Gastroenterol 2006; 44 (1): 43-49
59. Morimoto O, Nagano H, Sakon M et al. Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas. J Hepatol 2003; 39 (2): 215-221
60. Imamura H, Matsuyama Y, Tanaka E et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003; 38 (2): 200-207
61. Sasaki Y, Yamada T, Tanaka H et al. Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B- or hepatitis C-related hepatocellular carcinoma. Ann Surg 2006; 244 (5): 771-780
62. Schwartz JD, Schwartz M, Mandeli J et al. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 2002; 3 (10): 593-603
63. Lai EC, Lo CM, Fan ST et al. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg 1998; 133 (2): 183-188
64. Piao CY, Fujioka S, Iwasaki Y et al. Lamivudine treatment in patients with HBV-related hepatocellular carcinoma - using an untreated, matched control cohort. Acta Med Okayama 2005; 59 (5): 217-224
65. Kubo S, Tanaka H, Takemura S et al. Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. Hepatol Res 2007; 37 (2): 94-100
66. Sun HC, Tang ZY, Wang L et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006; 132 (7): 458-465
67. Lin SM, Lin CJ, Hsu CW et al. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004; 100 (2): 376-382
68. Kubo S, Nishiguchi S, Hirohashi K et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001; 134 (10): 963-967
69. Uenishi T, Nishiguchi S, Tamori A et al. Influence of interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma. Hepatol Res 2006; 36 (3): 195-200
70. Kubo S, Hirohashi K, Tanaka H et al. Risk factors for recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. World J Surg 2000; 24 (12): 1559-1565
71. Shiratori Y, Shiina S, Teratani T et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003; 138 (4): 299-306
72. Mazzaferro V, Romito R, Schiavo M et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006; 44 (6): 1543-1554
73. Cornberg M, Protzer U, Dollinger MM et al. Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus- (HBV-)Infection: upgrade of the guideline, AWMF-Register 021/011. Z Gastroenterol 2007; 45 (6): 525-574
74. Muto Y, Moriwaki H, Ninomiya M et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996; 334 (24): 1561-1567
75. Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 1999; 340 (13): 1046-1047
76. Lau WY, Leung TW, Ho SK et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999; 353 (9155): 797-801
77. Boucher E, Corbinais S, Rolland Y et al. Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology 2003; 38 (5): 1237-1241
78. Partensky C, Sassolas G, Henry L et al. Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma: a phase 2 clinical study. Arch Surg 2000; 135 (11): 1298-1300
79. Takayama T, Sekine T, Makuuchi M et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356 (9232): 802-807
80. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24 (26): 4293-4300
81. Kawata S, Yamasaki E, Nagase T et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001; 84 (7): 886-891
82. Lersch C, Schmelz R, Erdmann J et al. Treatment of HCC with pravastatin, octreotide, or gemcitabine - a critical evaluation. Hepatogastroenterology 2004; 51 (58): 1099-1103
83. Jonas S, Bechstein WO, Steinmuller T et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33 (5): 1080-1086
84. Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33 (6): 1394-1403
85. Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 1999; 19 (3): 311-322
86. Bernal E, Montero JL, Delgado M et al. Adjuvant chemotherapy for prevention of recurrence of invasive hepatocellular carcinoma after orthotopic liver transplantation. Transplant Proc 2006; 38 (8): 2495-2498
87. Otto G, Heise M, Moench C et al. Transarterial chemoembolization before liver transplantation in 60 patients with hepatocellular carcinoma. Transplant Proc 2007; 39 (2): 537-539
88. Decaens T, Roudot-Thoraval F, Bresson-Hadni S et al. Impact of pre-transplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl 2005; 11 (7): 767-775
89. Leckel K, Beecken WD, Jonas D et al. The immunosuppressive drug mycophenolate mofetil impairs the adhesion capacity of gastrointestinal tumour cells. Clin Exp Immunol 2003; 134 (2): 238-245
90. Schumacher G, Oidtmann M, Rosewicz S et al. Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. Transplant Proc 2002; 34 (5): 1392-1393
91. Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8 (2): 128-135
92. Koehl GE, Andrassy J, Guba M et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004; 77 (9): 1319-1326
93. Kneteman NM, Oberholzer J, Al Saghier M et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004; 10 (10): 1301-1311
94. Hojo M, Morimoto T, Maluccio M et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397 (6719): 530-534
95. Donckier V, Troisi R, Toungouz M et al. Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft. Transpl Immunol 2004; 13 (2): 139-146
96. DKFZ. Krebsatlas. 2006. www.dkfz.de/epi/Home_d/Programm/AG/ Praevent/Krebshom/main/deutsch/frame5.html
97. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362 (9399): 1907-1917
98. Oon CJ. Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions. Cancer Chemother Pharmacol 1992; 31 (Suppl): S137-142
99. Mazzella G, Accogli E, Sottili S et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996; 24 (2): 141-147
100. International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998; 351 (9115): 1535-1539
101. Yuen MF, Hui CK, Cheng CC et al. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001; 34 (1): 139-145
102. Nishiguchi S, Kuroki T, Nakatani S et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346 (8982): 1051-1055
103. Fattovich G, Giustina G, Degos F et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1997; 27 (1): 201-205
104. Valla DC, Chevallier M, Marcellin P et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 1999; 29 (6): 1870-1875
105. Shiratori Y, Ito Y, Yokosuka O et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005; 142 (2): 105-114
106. Someya T, Ikeda K, Saitoh S et al. Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis. J Gastroenterol 2006; 41 (12): 1206-1213
107. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127 (5 Suppl 1 ): S27-34
108. Perz JF, Armstrong GL, Farrington LA et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45 (4): 529-538
109. Chang MH, Shau WY, Chen CJ et al. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. Jama 2000; 284 (23): 3040-3042
110. Ni YH, Chang MH, Huang LM et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001; 135 (9): 796-800